Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 1:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 13,123 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Genitourinary System; Disorder, Female Clear all
Completed Phase 4 Interventional Results available

Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes

NCT02964585
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
George Washington University
Other
Eligibility
30 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Sep 22, 2026, 1:02 AM EDT
Completed Not applicable Interventional Results available

Post-Approval Study for the FLAIR Endovascular Stent Graft

NCT00677235
View directory record Official record
Conditions
Stenosis of Vascular Prosthetic Devices, Implants and Grafts
Interventions
FLAIR Endovascular Stent Graft, PTA
Device · Procedure
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Bamberg, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 22, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

NCT00847015
View directory record Official record
Conditions
Bladder Cancer, Urinary Bladder
Interventions
Sunitinib, Gemcitabine, cisplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 22, 2026, 1:02 AM EDT
Withdrawn Phase 2 Interventional

Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)

NCT01893658
View directory record Official record
Conditions
Acute Interstitial Nephritis
Interventions
Omalizumab, Prednisone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Sep 22, 2026, 1:02 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Determination of Kidney Function

NCT00001978
View directory record Official record
Conditions
Kidney Disease, Proteinuria, Autoimmune / Connective Tissue Diseases
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
7 Years and older
Enrollment
456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1989 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 22, 2026, 1:02 AM EDT
Recruiting Not applicable Interventional

Serial MRI Scans During Radiation Therapy

NCT04188535
View directory record Official record
Conditions
Glioblastoma, Esophageal Cancer, Radiotherapy, Magnetic Resonance Imaging, MRI, Prostate Cancer, Vulvar Cancer, Pediatric Glioblastoma Multiforme, Sarcoma
Interventions
MRI IMAGING
Diagnostic Test
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 22, 2026, 1:02 AM EDT
Completed Not applicable Interventional

Vegetable Garden Feasibility Trial to Promote Function in Older Cancer Survivors

NCT02150148
View directory record Official record
Conditions
Cancer
Interventions
Experimental: Mentored Gardening Intervention
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
60 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Sep 22, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

NCT01108055
View directory record Official record
Conditions
Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy), Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
Interventions
Pazopanib (GW786034), Paclitaxel
Drug
Lead sponsor
Sandy Srinivas
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Stanford, California • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Sep 22, 2026, 1:02 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

NCT04442126
View directory record Official record
Conditions
Advanced Solid Tumor, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma, Ovarian Carcinoma, Peritoneal Carcinoma, Fallopian Tube Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer
Interventions
NM21-1480
Biological
Lead sponsor
Numab Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
14
States / cities
Fort Collins, Colorado • Augusta, Georgia • New Orleans, Louisiana + 11 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 22, 2026, 1:02 AM EDT
Completed Phase 3 Interventional

Homocysteine Study (HOST)

NCT00032435
View directory record Official record
Conditions
End Stage Renal Disease, Renal Failure
Interventions
PAL-40 Active, PAL-40 Placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years and older
Enrollment
2,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
36
States / cities
Birmingham, Alabama • Menlo Park, California • Palo Alto, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2010 · Synced Sep 22, 2026, 1:02 AM EDT
Completed Phase 4 Interventional Results available

Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease

NCT01974817
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
13-valent conjugate pneumococcal vaccine
Biological
Lead sponsor
Michigan State University
Other
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Sep 22, 2026, 1:02 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Continuation of the nuMoM2b Heart Health Study

NCT05472597
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Not listed
Lead sponsor
RTI International
Other
Eligibility
18 Years and older · Female only
Enrollment
4,048 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
14
States / cities
Orange, California • Newark, Delaware • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 22, 2026, 1:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Uterine Cooling During Cesarean Delivery to Reduce Blood Loss and Incidence of Postpartum Hemorrhage

NCT02229513
View directory record Official record
Conditions
Postpartum Hemorrhage, Uterine Atony
Interventions
Uterine Cooling
Procedure
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Sep 22, 2026, 1:02 AM EDT
Completed Phase 1 Interventional

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

NCT02892123
View directory record Official record
Conditions
HER2-expressing Cancers
Interventions
ZW25 (Zanidatamab), Paclitaxel, Capecitabine, Vinorelbine, Tucatinib
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 22, 2026, 1:02 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

NCT03459846
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Durvalumab, Olaparib, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
12
States / cities
Birmingham, Alabama • Goodyear, Arizona • Fort Myers, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 22, 2026, 1:02 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Preventing Health Damaging Behaviors in Male and Female Army Recruits

NCT01234103
View directory record Official record
Conditions
Sexually Transmitted Infection (STI) Prevention, Unintended Pregnancy Prevention, Sexual Risk Reduction, Alcohol and Other Substance Use Prevention, Intimate Partner Violence Prevention
Interventions
Preventing Helath Damaging Health Behaviors in Male and Female Army Recruits
Behavioral
Lead sponsor
United States Department of Defense
Federal
Eligibility
18 Years and older
Enrollment
933 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Sep 22, 2026, 1:02 AM EDT
Terminated Phase 1 Interventional

Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.

NCT00565227
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma, Prostate Cancer, Bladder Cancer, Urothelial Carcinoma
Interventions
vorinostat (suberoylanilide hydroxamic acid), docetaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Sep 22, 2026, 1:02 AM EDT
Withdrawn No phase listed Observational

New Urine and Blood Markers for Acute Kidney Injury in Liver Transplant Patients

NCT00855127
View directory record Official record
Conditions
Renal Insufficiency, Acute
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 31, 2015 · Synced Sep 22, 2026, 1:02 AM EDT
Enrolling by invitation Not applicable Interventional

Genetic Education in BRCA Families

NCT03544983
View directory record Official record
Conditions
BRCA1 Mutation, BRCA2 Mutation
Interventions
Web + Streamlined Telephone Genetic Information
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
21 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 22, 2026, 1:02 AM EDT
Completed Phase 2 Interventional

Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix

NCT00031993
View directory record Official record
Conditions
Cervical Squamous Cell Carcinoma, Recurrent Cervical Cancer
Interventions
erlotinib hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Sep 22, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma

NCT00496587
View directory record Official record
Conditions
Renal Cell Carcinoma, Kidney Cancer
Interventions
Capecitabine, Gemcitabine, Bevacizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Sep 22, 2026, 1:02 AM EDT
Not listed Phase 1Phase 2 Interventional

Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

NCT01154387
View directory record Official record
Conditions
End Stage Renal Disease, Renal Transplant
Interventions
Anti-Thymocyte Globulin, TOL101, Steroids, Tacrolimus, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Tolera Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
12
States / cities
Aurora, Colorado • Lexington, Kentucky • Ann Arbor, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Sep 22, 2026, 1:02 AM EDT
Terminated Phase 3 Interventional Results available

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain

NCT04372121
View directory record Official record
Conditions
Endometriosis
Interventions
75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
Drug
Lead sponsor
Kissei Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
23
States / cities
Little Rock, Arkansas • Norwalk, California • Greenwood Village, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 22, 2026, 1:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Systematized Quality Exercise Alternatives for Stress Incontinence

NCT03443687
View directory record Official record
Conditions
Stress Urinary Incontinence, Pelvic Floor; Weak, Incontinence, Urinary, Quality of Life
Interventions
Pelvic Floor Physical Therapy, Home Biofeedback
Behavioral · Device
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 22, 2026, 1:02 AM EDT